Modified GRF (1–29) / Ipamorelin Blend is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Modified GRF (1–29) and Ipamorelin. Modified GRF (1–29) is a stabilized analog of growth hormone–releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist. Together, this blend is formulated for laboratory research focused on pulsatile growth hormone release, receptor signaling pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, Modified GRF (1–29) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a short duration of activity. Ipamorelin has been examined for its selective receptor activity and minimal interaction with other pituitary hormones. The combination allows researchers to examine complementary mechanisms involved in growth hormone pulsatility, secretion dynamics, and endocrine signaling coordination.
Currently, the Modified GRF (1–29) / Ipamorelin Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic signaling, circadian hormone release patterns, and coordinated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Modified GRF (1-29), Ipamorelin Blend is designed for laboratory research examining growth hormone signaling pathways, hypothalamic–pituitary axis communication, and endocrine biomarker responses within controlled experimental environments. By combining a growth hormone–releasing hormone analog with a growth hormone secretagogue, researchers can evaluate how complementary signaling pathways influence pulsatile GH release patterns and hormone signaling dynamics.
Multi-peptide research protocols are commonly used to investigate how upstream hypothalamic signaling interacts with pituitary hormone response mechanisms. When properly structured, these experimental models can provide insight into hormone pulse behavior, endocrine pathway communication, and biomarker changes associated with GH-axis activity.
Modified GRF (1-29), Ipamorelin Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Modified GRF (1-29) + Ipamorelin |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Modified GRF (1-29) is commonly referenced in peptide research as a growth hormone–releasing hormone analog used to study pulsatile growth hormone release and hypothalamic–pituitary signaling pathways. In controlled research environments, investigators may evaluate how upstream GHRH stimulation affects hormone pulse timing, amplitude, and endocrine marker responses.
Ipamorelin is a growth hormone secretagogue studied for its interaction with ghrelin receptor pathways involved in pituitary hormone signaling. In laboratory models, this peptide is often examined to understand how secretagogue-driven signaling influences GH-axis activity and downstream metabolic biomarkers.
When these peptides are combined within a research protocol, investigators can evaluate how GHRH pathway activation interacts with ghrelin receptor signaling. Experimental studies often measure hormone release patterns and endocrine biomarker fluctuations to understand how multiple signaling inputs affect growth hormone pathway dynamics.
Researchers interested in studying each compound independently can reference the product pages for CJC-1295 (without DAC) (commonly associated with Modified GRF research) and Ipamorelin.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
A central research objective for this peptide blend is evaluating pulsatile growth hormone release patterns. Researchers may measure endocrine marker changes across timed sampling intervals to observe how combined pathway activation influences hormone signaling dynamics.
Because Modified GRF (1-29) stimulates upstream GHRH pathways and Ipamorelin activates ghrelin receptor signaling, this blend provides a useful experimental model for studying communication within the hypothalamic–pituitary endocrine axis.
GH-axis studies frequently evaluate downstream biomarkers associated with hormone signaling. In controlled research environments, investigators may analyze endocrine marker fluctuations associated with peptide pathway activation.
Many experimental frameworks compare blended peptide protocols with single-peptide conditions. This research structure allows investigators to determine whether observed signaling responses arise from individual pathways or interactions between multiple endocrine inputs.
The Modified GRF (1-29), Ipamorelin Blend should be handled according to standard peptide laboratory procedures emphasizing contamination prevention, stable storage conditions, and detailed experimental documentation. Maintaining controlled laboratory environments helps ensure reproducible research outcomes.
Protocol Design Considerations: Growth hormone signaling research is sensitive to circadian rhythm timing, baseline metabolic status, environmental conditions, and stress variables. Carefully controlled experimental environments and standardized sampling windows help maintain reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports support procurement verification, regulatory documentation, and reproducibility tracking across research studies.
Laboratories sourcing peptides for endocrine signaling research typically prioritize traceable documentation, consistent synthesis standards, and strict quality-control procedures. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and manufacturing standards designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
